Showing results (231-240 of 292) with videos related to
Sort By:
Pageof 30
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 28, 2012
Terminal patients in Belgian nursing homes: a cost analysisSteven Simoens, Betty Kutten, Emmanuel Keirse, et al.Journal of Pain and Symptom Management|June 29, 2010
The costs of treating terminal patientsSteven Simoens, Betty Kutten, Emmanuel Keirse, et al.Journal of Market Access & Health Policy|June 25, 2026
Joint Clinical Assessment in the EU HTA Regulation-Would Drugs Supported by Single-Arm Trials Fit Under Evaluation?Krzysztof Kloc, Mondher Toumi, Elżbieta Łukomska, et al.Journal of Market Access & Health Policy|May 27, 2026
EU-HTA-Why Do Words Matter?Mondher Toumi, Bruno Falissard, Steven Simoens, et al.Ophthalmology and Therapy|February 26, 2025
Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative ReviewSeenu M Hariprasad, Frank G Holz, Carl V Asche, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|September 2, 2021
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique surveyEline van Overbeeke, Brett Hauber, Sissel Michelsen, et al.Respiratory Medicine|February 19, 2010
Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practiceGert Laekeman, Steven Simoens, Johan Buffels, et al.Gastroenterology|March 1, 2015
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel diseaseNiels Vande Casteele, Marc Ferrante, Gert Van Assche, et al.Journal of Medical Economics|May 20, 2009
Do tariffs and prices correspond with costs? A case study of orthotic bracesSteven Simoens, Hans Debruyne, Ingrid Moldenaers, et al.Frontiers in Pharmacology|December 13, 2019
Reimbursement Status and Recommendations Related to Orphan Drugs in European CountriesEwa Stawowczyk, Krzysztof Piotr Malinowski, Paweł Kawalec, et al.Pageof 30